Wire Stories

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”

The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver greater precision in the diagnosis and surgical management of urological cancers.

MELBOURNE, Australia & PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) a biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA, ‘Mauna Kea’) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced an exclusive scientific and clinical research collaboration in the field of molecular imaging guided urologic oncology.

The Telix and Mauna Kea scientific and clinical research collaboration is called the “Imaging and Robotics in Surgery (IRiS) Alliance,” or “IRiS Alliance,” and was created to further develop the combined technological capabilities of both companies. The IRiS Alliance was formed based on the belief that the use of cancer-specific Positron Emission Tomography (PET) imaging agents, including dual-modality tracers that combine PET and fluorescent (optical) techniques, in conjunction with confocal laser endomicroscopy, may significantly improve surgical techniques and clinical outcomes in patients with urologic cancers.

The IRiS Alliance aims to demonstrate that pre-operative planning, intra-operative guidance, surgical margin assessment and other surgical parameters may be improved by combining these modalities. The initial focus of the IRiS Alliance is to develop and evaluate the use of Telix’s dual-modality PET and optical imaging tracers, together with Mauna Kea’s unique near-infrared version of the Cellvizio endomicroscopy platform to facilitate fluorescence-guided surgical interventions for prostate and kidney cancers.

“We are excited to announce this exclusive scientific and clinical research collaboration with Telix in the field of urologic oncology,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “The IRiS Alliance endeavors to combine the strengths of Telix’s molecular targeting, together with Cellvizio’s real-time in vivo cellular imaging, to bring dual modality molecular imaging to the operating theatre for the first time. The IRiS Alliance aims to significantly transform how the urologic surgeon will evaluate, target, excise, and confirm surgical margins at the cellular level. Our collaboration will further empower surgeons to fight cancers and save lives. We expect to begin pre-clinical and clinical feasibility studies in 2021.”

“The cutting-edge techniques our respective companies have developed in molecular targeting and real-time in vivo cellular imaging have a natural synergy and we are extremely pleased to have formalized this ground-breaking partnership,” said Christian Behrenbruch, Chief Executive Officer and Managing Director of Telix Pharmaceuticals Limited. “Through the IRiS Alliance, Telix and Mauna Kea together aim to deliver quantum improvements in surgical techniques and clinical outcomes in patients with urologic cancers, starting with prostate and kidney cancers, with the ultimate objective of improving the lives of the patients we serve.”

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in prostate, renal and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, and China. For more information on Mauna Kea Technologies, visit www.maunakeatech.com


Telix Pharmaceuticals Limited

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction.

Mauna Kea Technologies

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on August 7, 2020 under number 926346434_20200807 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.


Mauna Kea Technologies
United States
Mike Piccinino, CFA

Westwicke, an ICR Company


France and Europe
NewCap - Investor Relations

Thomas Grojean

+33 (0)1 44 71 94 94

[email protected]

Telix Corporate Contact
Dr. Christian Behrenbruch

Telix Pharmaceuticals Limited


[email protected]

Telix Investor Relations
Dr. David N. Cade

Telix Pharmaceuticals Limited

CBO & Head of Investor Relations

[email protected]

To Top